In conclusion, this study emphasizes that m6A methylation modification is significantly correlated with tumor immunophenotype and anti-PD-L1 immunotherapy response, and established m6A modification characteristics may help predict the response to anti-PD-L1 immunotherapy. The gene discussed is CD274; the disease is neoplasm.